

# Suitability of ScanRDI<sup>®</sup> as a Rapid Sterility Testing Method



## Table of Contents

3	Eagle ScanRDI® Sterility Test Protocol <i>Ross Caputo, PhD</i>
4	Evaluation of the ScanRDI® as a Rapid Alternative to the Pharmacopeial Sterility Test Method: Comparison of the Limits of Detection <i>Smith, R., Von Tress, M., Tubb, C., &amp; Vanhaecke, E.</i>
6	Sterility Testing: Compendial and Alternative Rapid Methods <i>David Hussong, PhD</i>
9	ScanRDI® System Performance Data as a Sterility Test Method for Pharmacy Compounded Preparations: A Ten Year Survey <i>Ross Caputo, PhD, and David Hussong, PhD</i>
15	USP Stimuli to the Revision Process: The Development of Compendial Rapid Sterility Tests <i>Members of the USP Modern Microbiological Methods Expert Panel</i>



## Eagle ScanRDI® Sterility Test Protocol

Ross Caputo, PhD, President at Eagle

### Would your sterile compounding process pass an FDA inspection?

In order to fully comply with USP <797>, a compounding pharmacy creating sterile preparations must develop its own formal quality assurance (QA) program. The characteristics of a QA program require the consideration of environmental testing and preparation verification results, with the recommended testing method outlined by USP <71>.

Because the compendial method of testing takes 14 to 18 days to complete, it is extremely limiting in the compounding industry. A sterile compound with a standard 30 day beyond-use date (BUD) will lose approximately half of its shelf life due to sterility testing. This delay may discourage compounders from developing or adhering to a QA program, leaving them at risk of failing an FDA inspection.

However, there is a faster way to comply with USP <797> and ensure your patients are receiving quality compounds. The ScanRDI Sterility Test Protocol is an FDA-accepted alternative to the official compendial sterility test method. ScanRDI rapidly detects viable microbial cells down to one microorganisms without the need for growth or cell multiplication. This removes the extended incubation period included in the USP <71> test method, so results are ready in just one day.

According to USP General Notices, alternate testing methods may be used if they can be shown to provide equivalent or better results. ScanRDI uses the same sampling protocols as USP <71>, detects all of the standard USP organisms, and has been shown to provide consistent and reliable results.<sup>1</sup>

Additionally, ScanRDI fulfills the method suitability requirement as outlined in USP <1223>. A suitability test is performed on every unique drug formula sample submitted for ScanRDI testing. If the compound does not pass this suitability test, Eagle will inform the compounding pharmacist that it was incompatible with the ScanRDI method.

<sup>1</sup> Smith, R., Von Tress, M., Tubb, C., & Vanhaecke, E. (2010). Evaluation of the ScanRDI as a rapid alternative to the pharmacopoeial sterility test method: Comparison of limits of detection. *PDA Journal of Pharmaceutical Science and Technology*, 64(4), 356-363.

# Evaluation of the ScanRDI<sup>®</sup> as a Rapid Alternative to the Pharmacopeial Sterility Test Method: Comparison of the Limits of Detection

Smith, R., Von Tress, M., Tubb, C., & Vanhaecke, E. (2010). Evaluation of the ScanRDI as a rapid alternative to the pharmacopoeial sterility test method: Comparison of limits of detection. *PDA Journal of Pharmaceutical Science and Technology*, 64(4), 356-363.

**TABLE II**  
Paired T-Tests of Non-Inferiority of the ScanRDI<sup>®</sup> and Compendial Sterility Test

Organism	Difference between Mean MPN <sup>a</sup>	Standard Deviation	<i>n</i>	<i>z<sub>n</sub></i>	<i>P</i>	Lower Confidence Limit <sup>b</sup>
<i>Clostridium sporogenes</i>	0.05	0.29	24	3.518	0.0009	-0.050
<i>Propionibacterium acnes</i>	0.58	0.40	15	7.128	<0.0001	0.398
<i>Escherichia coli</i>	0.20	0.30	25	5.812	<0.0001	0.092
<i>Pseudomonas aeruginosa</i>	0.95	0.37	13	10.972	<0.0001	0.762
<i>Staphylococcus aureus</i>	0.39	0.29	14	7.067	<0.0001	0.251
<i>Bacillus subtilis</i>	0.43	0.23	12	8.904	<0.0001	0.308
<i>Aspergillus niger</i>	0.67	0.41	16	8.115	<0.0001	0.490
<i>Candida albicans</i>	0.64	0.46	13	6.278	<0.0001	0.412

<sup>a</sup> Mean log<sub>10</sub> MPN for ScanRDI minus mean log<sub>10</sub> MPN for compendial sterility method.


<sup>b</sup> The acceptance criteria were satisfied if the lower one-sided 95.25% confidence limit on the paired difference was less than -0.1549, which is log<sub>10</sub>(0.70).

**TABLE IV**  
Comparison of the Limits of Detection (cells/mL<sup>-1</sup>)

Organism	ScanRDI Method	Compendial Method
<i>Clostridium sporogenes</i>	0.000070	0.002992
<i>Propionibacterium acnes</i>	0.000153	0.002805
<i>Escherichia coli</i>	0.000805	0.003846
<i>Pseudomonas aeruginosa</i>	0.001172	0.017179
<i>Staphylococcus aureus</i>	0.000489	0.002871
<i>Bacillus subtilis</i>	0.000192	0.001832
<i>Aspergillus niger</i>	0.000690	0.003199
<i>Candida albicans</i>	0.000178	0.005370


**FIGURE 1**

Difference between mean concentrations of bacteria detected by ScanRDI and the compendial methods for each of eight bacteria. Data points falling within the shaded region would indicate that the ScanRDI method was inferior to the compendial sterility test method for detecting contaminants. Error bars represent the two 1-sided 95% confidence intervals.



**FIGURE 2**

Percent of culture tubes showing the presence of microorganisms at three dilution levels. Open symbols depict data collected using the ScanRDI method, while closed symbols depict data collected using the reference compendial sterility test method. Values alongside the names of organisms in the legend indicate the total number of tubes tested for a given organism. Horizontal lines (dashed or dotted) depict the overall mean for all organisms at a given dilution.





# Sterility Testing: Compendial and Alternative Rapid Methods

David Hussong, PhD, Chief Technical Officer at Eagle

## Introduction

The compendial USP <71> sterility tests are growth-based and require at least a 14-day incubation to yield results. This time requirement is not suitable for short-lived products or those prepared for immediate use that are frequently infused into patients before the completion of the compendial test. Additionally, this reduces the useable time period while adding significant cost to the release testing. To address the needs of stakeholders preparing compounded sterile preparations, radiopharmaceuticals, and cell and gene therapies, the USP Microbiology Expert Committee assessed and has proposed alternative test methods for addition to the compendia, including new-generation rapid sterility tests. The complete proposal will be published in Pharmacopeial Forum (September, 2017; 43(5)). This paper summarizes some findings related to the status of rapid sterility test methods.

## Background

With primary consideration of improved patient safety, USP has established user requirement specifications (URS) for rapid sterility tests. They determined that the URS are different for various therapies and diagnostics, and the means of producing those therapies by the four major users:

1. Sterile compounding
2. Positron emission tomography (and other short-lived radiopharmaceuticals)
3. Cell therapy
4. Traditional pharmaceutical manufacturing

## Findings

The USP has identified several technologies that are suitable for use as alternative, rapid sterility tests. These offer acceptable results to meet the user requirement specifications pending suitability assessment, just as the compendial <71> methods are subject to suitability testing with each product or product class. Additionally, there are various vendors for each technology. There are some platforms that have been in use for longer periods, and for which more data exists.



The following table provides a list of these technologies and suppliers:

Advanced Technology	Instrument Name	Vendor
ATP bioluminescence	Biotrace 2000 Pallcheck Rapid System Milliflex Rapid System Celsis RapiScan BioMAYTECTOR	Biotrace International, Brigend, UK Pall Corp., Port Washington, NY Millipore Corp., Bedford, MA Charles River Laboratories, Inc., Wilmington, MA Hitachi Plant Technologies, Tokyo, Japan
Flow cytometry	Bact-Flow FACSMicroCount	bioMerieux, Hazelwood, MO Becton, Dickerson & Co., Sparks, DE
Isothermal microcalorimetry	TAM III Calorimeter Biocal 2000 Isothermal Calorimeter 48-challen isothermal microcalorimeter	TA Instruments, Wilmington, DE Calimetrix, Arlington, MA SymCell Sverige, Kista, Sweden
Nucleic acid amplification	Multiple thermocyclers and amplificor analyzers	Roche Applied Science, Indianapolis, IN Applied Biosystems, Foster City, CA Cepheid, Sunnyvale, CA
Respiration	Promex Microrespirator 4200 BACTEC System BioLumix BacT/ALERT 3D Dual-T System eBDS Pall System TDLS	PromChem Ltd., Edenbridge, UK BD Diagnostics, Sparks, DE BioLumix, Ann Arbor, MI bioMerieux, Hazelwood, MO Pall Corp., Port Washington, NY Lighthouse Instruments, Charlottesville, VA
Solid phase cytometry	ScanRDI® System BioSafe PTS MuScan System	bioMerieux, Hazelwood, MO Charles River Laboratories, Inc., Wilmington, MA Innosieve Diagnostics, Wageningen, The Netherlands



Among the technologies is ScanRDI, a long-used solid-phase technology that has an established record for detection of filterable organisms in solutions or soluble products.<sup>1</sup> Cells are collected by filtration on 0.45-micron polyester membranes and treated with background and viability stains. The filters are scanned in a cytometer by a high-speed, 488 nM argon Laser. Fluorescence is detected by multiple photomultiplier tubes, processed to differentiate between labeled microorganisms and background noise. The scan is displayed as a map that identifies the position of the fluorescent events that are verified using an epifluorescence microscope with an automated motorized stage to locate the individual events. The system is claimed to identify individual viable microorganisms in 2-3 hours. Technologies using similar principles were accepted for clinical use beginning in 1987<sup>2</sup> and also offered the advantage of detecting senescent microorganisms not recoverable by cultivation.<sup>3,4</sup>

## Discussion

Rapid microbiology methods have been accepted for FDA approved products. Carticel, a cell therapy product, uses the BacT/Alert system that detects headspace gases generated during several days of incubation.<sup>5</sup> Similarly, the National Institutes of Health has used the Bactec system for clinical supply (ING) products.<sup>6</sup> Bactect also requires up to 14-days incubation but reliable product release results generally occur within 7-days. Although unpublished, there are approved drug applications using the ScanRDI for sterility tests for product release. This assay can yield results in one day. None of the rapid methods appear suitable for all products' needs, just as the compendial methods need to be adjusted for proper results. However, the alternative methods provide reliable results in less time. As noted in USP General Notices, section 6.30, Alternative and Harmonized Methods and Procedures, "Alternative methods and/or procedures may be used if they provide advantages in terms of accuracy, sensitivity, precision, selectivity, or adaptability to automation or computerized data reduction, or in other special circumstances."

## References

1. Smith, R., Von Tress, M., Tubb, C., & Vanhaecke, E. (2010). Evaluation of the ScanRDI as a rapid alternative to the pharmacopoeial sterility test method: Comparison of limits of detection. *PDA Journal of Pharmaceutical Science and Technology*, 64(4), 356-363.
2. Kronvall, G., and Myhre, E. (1977). Differential staining of bacteria in clinical specimens using acridine orange buffered at low pH. *Acta Pathologica et Microbiologica Scandinavica. Section B, Microbiology*, 85(4), 249-254.
3. Lauer, B. A., Reller, L. B., & Mirrett, S. (1981). Comparison of acridine orange and Gram stains for detection of microorganisms in cerebrospinal fluids and other clinical specimens. *Journal of Clinical Microbiology*, 14(2), 201-205.
4. Daley, R. J., & Hobbie, J. E. (1975). Direct counts of aquatic bacteria by a modified epifluorescence technique. *Limnology & Oceanography*, 20(5), 875-882.
5. Kiepinski, G., Prinzi, S., Duguid, J., & du Moulin, G. (2005). Roadmap to approval: Use of an automated sterility test method as a lot release test for Carticel, autologous cultured chondrocytes. *Cytotherapy*, 7(6), 531-541.
6. Khuu, H. M., Patel, N., Carter, C. S., Murray, P. R., & Read, E. J. (2006). Sterility testing of cell therapy products: Parallel comparison of automated methods with a CFR-compliant method. *Transfusion*, 46(12), 2071-2082.



# ScanRDI<sup>®</sup> System Performance Data as a Sterility Test Method for Pharmacy Compounded Preparations: A Ten Year Survey

Ross Caputo, PhD, President at Eagle

David Hussong, PhD, Chief Technical Officer at Eagle

## Abstract

Since 2007, Eagle has utilized the ScanRDI system to determine the sterility of pharmacy compounded products. During this time period nearly 40,000 tests have been performed, encompassing nearly 1500 different drug compound categories for nearly 500 different pharmacy locations. This is believed to be the most complex data set ever accumulated. Of the products tested 0.96% (383) were found to be non-sterile, 96% sterile and 3.4% were found to be incompatible (no test) with the process. The data indicated that there was no statistical difference between pharmacy locations for the same product preparations compounded nor was there a difference in data between trained Eagle scientists. During this same time period traditional sterility testing outlined in USP 71 was also performed. During this time period over 45000 tests were performed for approximately 1000 different pharmacy locations over 1500 drug compound categories. The sterility positive rate was .63% (288) This evaluation suggests that the Eagle ScanRDI method functions as an effective, efficient, alternative to the USP Sterility test method.

## Introduction

Proposed USP <797> revisions will dramatically reduce current beyond use dates (BUDs) for sterile compounded preparations.<sup>1</sup> Finished product testing required to assign the maximum allowable BUD requires a final preparation sterility test to be performed. The United States Pharmacopeia (USP) test for sterility, USP <71>, requires a minimum of 14 days for completion and can take up to 18 days, which could severely affect the availability of compounded preparations. For example, in the absence of a sterility test, sterile compounded preparations are permitted a BUD of 4 to 6 days when stored at room temperature. Once a sterility test has been completed, however, the permitted BUD extends to 42 days. Even if these dates are ultimately extended, it is apparent that it is critical to minimize the testing period so as to ensure the delivery/dispensing of prescribed products to the patient within the required time of not only dispensing but patient use.



Since 2004, Eagle has used and perfected the ScanRDI analyzer for the sterility testing of compounded product preparations. This system is the subject of an FDA Type V Drug Master File (DMF 14621) which contains data to support the technology for the detection of bacteria, spores, yeasts, and molds.<sup>2</sup> This master file also contains the validation data for the process of water microbial analysis, which supports previously published data.<sup>3</sup> Using this process, a sterility test can be performed in one day. Eagle now presents data compiled from using the ScanRDI system over a decade for sterility testing, analysis, and research on unique patient-specific sterile compounds prepared in multiple pharmacy locations. The data show that ScanRDI performance supports the utilization of this method for the sterility testing of compounded preparations.

### Method

All samples were prepared and managed in conformance with Eagle's standard operating procedures. This was, in the beginning, a research procedural system focused on the research associate documenting what was performed. As procedures were developed, they were codified but as with all dynamic operations a functional change control system exists for tracking effective dates for all procedures. The ScanRDI units were installed by the manufacturer who was also tasked with the performance of Installation Qualification, Operational Qualification, and Performance Qualification (IQ/OQ/PQ), to include final reports. All recommended maintenance is performed, and has always been, on contract by the manufacturer. All reagents and supporting material are supplied by the manufacturer. All personnel involved in the performance of tests are trained directly by the manufacturer. Only degreed scientists have been trained to use this system.


As a summary, the ScanRDI system can be described as follows. ScanRDI uses a combination of fluorescent labeling and solid phase laser cytometry to identify viable microorganisms from filterable samples. The system sensitivity can detect a single cell within 3 hours. Proprietary stains which consist of non-fluorescent membrane permeant substrates are used which are cleaved by non-specific esterases and retained in viable cells. This accumulated measurable chromophore is then detected during the laser scanning step in the ScanRDI analyzer. Within 3 minutes, results are displayed without operator interpretation. Some products are incompatible with this system due to auto fluorescence of the preparation. The unit will automatically indicate incompatibility, and the results would not be reported as a sterility failure. A scan map display showing the precise location of each organism for visual confirmation is a system microscope option that is used by Eagle to confirm all results. The reader is referred to the manufacturer for a more detailed description of the operation.<sup>4</sup>

## Results

### Breakup of Tests — ScanRDI and USP <71>


Of the 85,211 sterility tests conducted over the time period studied:

- 39,689 (46.58%) were ScanRDI rapid sterility tests
- 45,522 (53.42%) were USP <71> 14-day sterility tests



### Fails/Positives — ScanRDI and USP <71>

	ScanRDI	USP <71>
Pass (Negative)	37,955	45,234
Percent of Total	95.63%	99.37%
Fail (Positive)	383	288
Percent of Total	0.97%	0.63%
Incompatible	1,351	--
Percent of Total	3.40%	--
<b>Total</b>	<b>39,689</b>	<b>45,522</b>




■ ScanRDI Method

■ USP <71> Method



## Results


### Number of Tests — ScanRDI and USP <71> Over Time





## Results


### Number of Tests — ScanRDI and USP <71> Over Time





## Results

### Top 10 Categories for Samples Failed



## Conclusion

As described by Smith, "...the ScanRDI method is appropriate for use as a rapid alternative to the growth-based sterility test method."<sup>5</sup> Furthermore, given short beyond-use dating requirements, Eagle is not aware of any other option than the ScanRDI method at this time which has been evaluated as extensively with such a large data base of this specific use to evaluate end product sterility of compounded preparations.

## References

1. United States Pharmacopeial Convention (2018). <797> pharmaceutical compounding – Sterile preparations [In-process revision: General chapters]. *Pharmacopeial Forum*, 44(5). Retrieved from <http://www.usppf.com/pf/pub/>
2. bioMérieux (n.d.). *FDA Drug Master File #14621*.
3. Jones, D. L., Brailsford, M. A., & Drocourt, J.-L. (1999) Solid-phase, laser-scanning cytometry: A new two-hour method for the enumeration of microorganisms in pharmaceutical water. *Pharmacopeial Forum*, 25, 7626-7645.
4. bioMérieux (n.d.). *ScanRDI®*. Retrieved from <http://www.biomerieux-industry.com/biopharma/scanrdi>
5. Smith, R., Von Tress, M., Tubb, C., & Vanhaecke, E. (2010). Evaluation of the ScanRDI as a rapid alternative to the pharmacopeial sterility test method: Comparison of limits of detection. *PDA Journal of Pharmaceutical Science and Technology*, 64(4), 356-363.

# USP STIMULI TO THE REVISION PROCESS

*Stimuli articles do not necessarily reflect the policies of the USP or the USP Council of Experts.*

## The Development of Compendial Rapid Sterility Tests

Members of the USP Modern Microbiological Methods Expert Panel

### Abstract

An Expert Panel was formed under the USP General Chapters—Microbiology Expert Committee to provide recommendations on user requirements specifications (URS) and candidate technologies based on the URS in the area of rapid sterility tests. The Expert Panel provided recommendations for the critical URS for candidate rapid sterility tests, which were: 1) the ability to detect a wide range of microorganisms, i.e., specificity; 2) detection of a low number of microorganisms, i.e., limit of detection; 3) time to result; 4) improved patient safety; 5) sample preparation; and 6) sample quantity, i.e., minimum number of articles tested and quantity per container tested. Based on a review of these user requirements, the Expert Panel recommended that adenosine triphosphate bioluminescence, flow cytometry, isothermal microcalorimetry, nucleic acid amplification, respiration, and solid-phase cytometry advance as candidates for proof-of-concept studies to develop risk-based compendial rapid sterility tests.

### Introduction

It is widely recognized that the current growth-based sterility tests in *Sterility Tests* <71><sup>1</sup> with at least a 14-day incubation period are not suitable for short-lived products or those prepared for immediate use or administered to patients before the completion of the compendial sterility test. To address the needs of stakeholders making compounded sterile preparations, radiopharmaceuticals, and cell and gene therapies, the USP Microbiology Expert Committee has begun work on the development of a new generation of rapid compendial sterility tests.

### Background

With the primary consideration of improved patient safety, the Expert Panel began by establishing the user requirements specifications (URS) for rapid sterility tests. The consensus reached was that not all URS were the same for four main stakeholder groups indicated above. Therefore, URS were established for: 1) sterile compounding; 2) positron emission tomography (PET) drugs and other short-lived radiopharmaceuticals; 3) cell therapy; and 4) traditional pharmaceutical manufacturing.

Once the URS were established, the Expert Panel recommended the most suitable technologies or analytical platforms as candidates for a compendial rapid sterility test for proof-of-concept studies. Where analytical platforms were dependent upon instruments and reagents supplied by vendors, only non-proprietary technologies marketed by two or more instrument manufacturers were considered as potential candidates. The Expert Panel acknowledges that one or more of these analytical platforms may be found to have insurmountable technical limitations, which may prevent them from becoming compendial test methods. Despite being compendial tests, the rapid sterility tests would need to meet method suitability testing requirements for each pharmaceutical and biological product and would be subject to review in their regulatory submissions.

### History of USP Sterility Tests

It is useful to review the history of how the USP sterility tests evolved.<sup>2,3,4</sup> *Table 1* contains a brief summary of the development of <71> from 1936–2009.

**Table 1:**

Compendial Revision	Brief Description of the Sterility Test
<i>USP XI (1936), page 469, Tests for the Sterility of Liquids</i>	7-day incubation in 37° in a beef extract-peptone-dextrose broth
<i>USP XII (1941), Sterility Test for Solids added</i>	Additions: broth for sterility tests under anaerobiosis, inactivating fluids, and a honey medium for molds and yeast incubated at 22° - 22° for 15 days
<i>USP XVII (1965), pages 829-832, Sterility Test</i>	Additions: fluid thioglycollate medium incubated at 30°-32° for 7 days, fluid Sabouraud dextrose medium incubated at 22° - 25° for 10 days, and bacteriostasis and fungistasis testing added to demonstrate the suitability of the method for each specific product
<i>USP XVIII (1970), pages 851-857, Sterility Tests</i>	Revisions: fluid thioglycollate medium incubated at 30°-35° for 14 days for aseptically filled products and 7 days for terminally sterilized products; soybean-casein digest medium incubated at 20°-25° for aseptically filled products and 7 days for terminally sterilized products; and the incubation period reduced from 14 to 7 days for membrane filtration sterility tests
<i>USP 27 (2004) pages 2157-2162, Sterility Tests &lt;71&gt;</i>	Harmonization: effective January 1; however, the compendial sterility tests contained 11 local non-harmonized requirements; all incubation times, regardless of product, were 14 days
<i>First Supplement to the USP 32 (2009), Sterility Tests &lt;71&gt;</i>	Revisions: the 11 local non-harmonized requirements were removed with an official date of August 1, 2009

## Limitations of the Selected Media

In general, microorganisms that are found in pharmaceutical drug products are present in low numbers and under stressed conditions due to 1) product formulation (especially the presence of antimicrobial agents or active ingredients); 2) manufacturing processes; and 3) physicochemical conditions such as low nutrient levels, pH (deviating from neutral), low-water activities, and exposure to temperatures above or below ambient temperature. To proliferate in microbiological growth media, microorganisms need to repair stress-induced damage, activate different biosynthetic and metabolic pathways, and acclimate to the media before they can enter a logarithmic growth phase.

Despite the belief that the sterility test media can support the growth of low numbers of stressed microbial cells, the media selection and incubation conditions of the compendial sterility test may not be optimal and may, in fact, be seriously compromised in an attempt to isolate the widest range of microorganisms (2). For example, fluid thioglycollate medium may be considered suboptimal for 1) strict and facultative anaerobes due to its aerobic incubation, 2) bacterial and fungal spore germination and growth, and 3) vegetative bacteria and fungi due to its low redox potential, medium viscosity, and component toxicity. Soybean–casein digest medium may be compromised for the isolation of skin-derived bacteria by the low incubation temperature, i.e., 20°–25°.

The unintended selectivity of the sterility test is illustrated by the common finding that the majority of sterility failures occur in only one of the two media when the microorganisms are capable of growth in both media. For example, 55% of the sterility failures had growth in the soybean-casein digest medium only, 33% grew in the fluid thioglycollate medium, and a mere 9% grew in both media<sup>5</sup> with over 30% of growth occurring between 7 and 14 days of incubation.<sup>6</sup>

## Sample Size Limitations

Chapter <71> defines the quantities of a pharmaceutical drug product per container to be tested per media and the number of units based on the batch size (see *Sterility Tests* <71>, *Table 2* and *3*, respectively). The number of vials tested is usually 20 or 40 units, depending on the fill volume of the containers. Considering the statistical power of the sample size with respect to a typical batch size in excess of 30,000 vials, the test is not capable of detecting a low microbial contamination rate associated with aseptically filled sterile drug products, i.e., there is only an 18% chance of detecting a 1% contamination rate<sup>4</sup> (see *Table 2*).

Furthermore, there are additional challenges with compounded sterile preparations, short-lived radiopharmaceuticals, and cell therapies compared to most pharmaceutical drug products. The lot sizes are usually small, the products must be used promptly, and sampling will deplete a significant portion of each lot, causing an economic loss and reduced availability of the material for patient treatment.

**Table 2: Probability of Failing the USP Sterility Test with Required Sample Size**

Frequency of Contaminated Units in a Batch	Probability of Failing the USP Sterility Test with Required Sample Size ( <i>Sterility Tests &lt;71&gt;</i> , Table 2 and 3)
1 in 1000	0.0198 (2%)
5 in 1000	0.0952 (9.5%)
1 in 100	0.1813 (18%)
5 in 100	0.6321 (63.2%)
1 in 10	0.8647 (86.5%)
5 in 10	1.000 (100%)

Currently, the minimum number of articles tested and quantity per container tested per media are defined in *Sterility Tests <71>*, Tables 2 and 3. This sampling plan is suitable for manufactured pharmaceuticals, but it depletes the batch, and is therefore unsuitable for products generated by sterile compounding pharmacies, PET facilities, and cell therapy centers because of their small batch size and the therapeutic value of the product to the individual patient. A further consideration is the sample size limitation of these advanced technologies.

Alternative sampling plans have been proposed in compendial chapters. The recommended approaches to sterility testing of cell therapy products can be found in *European Pharmacopoeia (EP)* 2.6.27 for batch sizes less than 40 units.

The *EP* provides 2.6.27 *Microbiological Examination of Cell-based Preparations* to use for cell therapies when the tests in 2.6.1 *Sterility* cannot be performed. These limitations may be due to the nature of the preparation, the process steps during which microbial contamination may be introduced, the short shelf-life of cell therapy products, the amounts available for testing, and sampling-related issues. *EP* positioned this test, not strictly as a sterility test, but as a test to screen for microbial contamination that may be better suited for certain situations. The chapter points out that with the use of a single donor or manufacturing-related capacity restraints, the sample volume available for testing may be limited. Microbial contamination can be missed if the sample size is not sufficient to ensure suitable sensitivity and specificity of the chosen test method.

The sample size for cell-based preparations, where the total infusible volume (V) is between 1 mL and 1 L in a single unit, is given in Table 3.

**Table 3: European Pharmacopoeia 2.6.27 Recommended Sample Sizes**

Cell-Based Preparation Volume (mL)	Total Test Sample Volume
10 < V < 1000	1% of the total volume
1 < V < 10	100 µL
V < 1	NA

In a manner similar to cell-therapy preparations, the sample quantity and sampling plan for PET radiopharmaceuticals must also accommodate the limited number of vials (usually 1) and the volume of product produced in a batch (usually less than 15 mL). If the batch consists of a single container, the sterility test sample size must be at least 1% of the total batch volume. For example, if a batch consists of 1 vial containing 15 mL, use at least 0.15 mL for purposes of the sterility test. If the batch consists of more than one container, use a volume from a single container that represents at least 1% of the total batch volume. If a batch consists of 3 vials each containing 25 mL, use at least 0.75 mL from 1 vial for purposes of the sterility test.

### **User Requirement Specifications**

Based on the work of the USP Expert Panel, 15 major user requirement specifications of different stakeholders were considered:

- Ability to detect a wide range of microorganisms, i.e., specificity
- Availability of instruments and reagents from multiple vendors
- Availability of Reference Standards
- Data integrity
- Ease of use/simplicity of test and data interpretation
- Low false-positive and false-negative rates
- Limit of detection
- Method suitability
- Improved patient safety
- Regulatory acceptance
- Robustness and reliability of equipment
- Sample preparation
- Sample quantity, i.e., minimum number of articles tested and quantity per container tested
- Time to result
- Aseptic test material handling, i.e., open vs. closed systems

### **Detailed Descriptions of the Most Challenging User Requirements**

Challenging user requirements specific to one or more stakeholder groups are:

- Ability to detect a wide range of microorganisms, i.e. specificity
- Limit of detection
- Time to result
- Improved patient safety
- Sample quantity, i.e., minimum number of articles tested and quantity per container tested
- Sample preparation
- Aseptic test material handling, i.e., open vs. closed systems

## Ability to Detect a Wide Range of Microorganisms

Although all the analytical platforms should have the ability to detect a wide range of bacteria, yeast, and mold, it is equally important to demonstrate that the rapid sterility test technology chosen is capable of detecting microorganisms implicated in sterility test failures, infection outbreaks, and product recalls associated with either compounded sterile preparations, radiopharmaceuticals, cell therapies, or manufactured pharmaceuticals. This is especially true if the technology, after risk analysis, is shown to improve patient safety with the administration of the products unique to that stakeholder group.

For example, a 2014 report from The Pew Charitable Trusts documented over 25 pharmacy compounding errors, the majority being microbial contamination associated, with 1,049 adverse events and 89 deaths since 2001. The report identified the bacterium *Serratia marcescens* as most frequently implicated in compounded sterile preparation infections<sup>7</sup>. In addition, a prospective, nationwide surveillance study of nosocomial bloodstream infections from U.S. hospitals over a 7-year period<sup>8</sup> implicated coagulase-negative staphylococci (31%), *Staphylococcus aureus* (20%), *Enterococcus* species (9%), *Candida* species (5%), *Escherichia coli* (3%), *Klebsiella* species (2%), and *Pseudomonas aeruginosa* (2%). The absence of strict anaerobes among microorganisms most responsible for bloodstream infections is notable and is considered to be due to the high levels of oxygenation of blood.

## Limit of Detection

Within the limitations of preparing inocula with one or more colony-forming units (cfu), growth-based sterility tests can be shown to have at least a theoretical limit of detection (LOD) of 1 cfu or 3 cfu based on a Poisson distribution. Setting an LOD of a single viable cell with all technologies is an unrealistic barrier to entry for any sterility test, especially when the signal is not the colony-forming unit that is amplified by cultural enrichment. The concept of an infectious dose is well established, especially in food and clinical microbiology.<sup>9</sup> Although the absence of viable microorganisms in the product has generally been accepted as a definition of sterility, there is little or no evidence that 1 cfu is an infectious dose (i.e., clinically significant) for injectable products. To the contrary, well-established evidence from the study of infection rates due to the administration of platelet concentrates to human cancer patients suggests that the infectious dose may be 10<sup>2</sup>–10<sup>3</sup> viable microorganisms, depending on the virulence of the microorganism. The study of transfusion infection with platelet concentrations provides an excellent test case to determine the infectious dose as they have an estimated contamination rate between 0.03% and 0.7%. In a unique study, Jacob et al (2008) determined the bacterial content of thousands of platelet concentrates immediately prior to infusion<sup>10</sup> and found that a detection threshold of at least 10<sup>3</sup> cfu/ML would detect more than 95% of all infection cases and

that a detection threshold of 102 cfu/mL would detect all cases (100%). These general findings were confirmed in a follow-up publication from the same researchers from Case Western University<sup>11</sup> and are generally accepted by the transfusion microbiology community.<sup>12</sup>

As noted by the authors of a recent study on the use of the 16S rRNA polymerase chain reaction (PCR) sterility test for stem cells with the demonstrated bacterial sensitivity of 10–100 cfu/mL, a test method with a sensitivity of 100 cfu/mL would be suitable to detect clinically significant bacterial contamination of blood and cell products.<sup>13</sup>

As noted by the authors of a recent study on the use of the 16S rRNA polymerase chain reaction (PCR) sterility test for stem cells with the demonstrated bacterial sensitivity of 10–100 cfu/mL, a test method with a sensitivity of 100 cfu/mL would be suitable to detect clinically significant bacterial contamination of blood and cell products.<sup>13</sup>

### **Time to Result**

The incubation time for growth-based <71> sterility tests is at least 14 days; this makes it unsuitable for PET and cell therapy as these short-life products would be administered before completion of the test. This time to result is marginally acceptable for sterile compounding, but generally suitable for pharmaceutical manufacturing. Some PET drugs may be administered immediately after preparation due to the short half-life of certain PET radionuclides, so a sterility test needs to be real time for this stakeholder group. The most commonly used PET radionuclide is fluorine-18, which is normally used within 12 h. For compounded sterile preparations and cell therapies, sterility tests need to be completed within a maximum of 48 h, especially when the dose is needed promptly for a waiting patient. Additionally, manufactured pharmaceuticals can be tested within 5–7 days to shorten the batch release cycle time. See *Table 4* for typical expiration dating.

### **Improved Patient Safety**

It is widely accepted that a rapid sterility test for compounded sterile preparations, radiopharmaceuticals, and cell therapies will improve patient safety, especially if contaminated materials can be detected before administration to patients. Furthermore, sterility test methods that continuously monitor for the presence of viable microorganisms during processing as a control strategy would be advantageous. Such monitoring after product release, with a reporting mechanism when a failure is detected, would enable the laboratory to alert the clinician, who could then intervene as necessary to protect the patient. The ability of a bacterial contaminant to grow in a product and its virulence when infused into a patient should both be considered.

**Table 4: Typical Beyond Use/Expiration Dating of Stakeholder Products**

Stakeholders	Representative Products	Beyond Use/Expiration Dating
Sterile compounding pharmacies	Low Risk: reconstitution and transfer of a 1-g vial of cefazolin into an IV bag Medium Risk: Distribution from a 10-g bulk pharmacy vial of vancomycin among several final doses High Risk: Patient-controlled analgesic from powdered morphine	Low Risk: 48 h (room temperature); 14 days (2°-8°); 45 days (frozen) Medium Risk: 30h (room temperature); 9 days (2°-8°); 45 days (frozen) High Risk: 24h (room temperature); 3 days (2°-8°); 45 days (frozen)
PET facilities	Fluorine-18 fluorodeoxyglucose (half-life of 110 min)	Cellular therapy products may be transported for administration in hours or days without cryopreservation, or stored in a cryopreserved state (<-30°) indefinitely.
Cell therapy facilities	Stem cells	Cellular therapy products may be transported for administration in hours or days without cryopreservation, or stored in a cryopreserved state (<-30°) indefinitely.
Pharmaceutical manufacturers	Numerous examples	2-3 years at ambient or refrigeration temperature

Other limitations of the compendial sterility test methods that may impact patient safety are as follows:

- The ability of the sterility test to be affected by antibiotics in the test sample
- The subjectivity of detecting microbial growth in microbiological culture broth
- The lack of detection of culture-negative infectious agents
- The unintended selectivity of culture media and the incubation temperature/conditions

Many compounded sterile preparations are antibiotics. Cell cultures used to produce cell and gene therapies may include antibiotics to control microbial contamination during aseptic manipulations such as cell culture expansion. As the mode of action of antibiotics usually involves the bacterial cell wall or protein synthesis, residual antibiotics in the sterility test media may inhibit bacterial growth leading to false-negative test results. Sterility test methods that are not growth-based generally are not affected by antibiotic residuals.

Microbial growth in broth will appear as turbidity, pellicles, floccular growth, or precipitation. However, the product may obscure the presence of microbial growth. It is estimated that cell densities exceeding 10<sup>6</sup> cfu/mL are needed to make the media turbid for detection by the naked eye. These assessments are highly subjective and that may result in false-negative test results.

Although rare, culture-negative infections are observed in clinical microbiology, and PCR and 16S rRNA gene sequencing have been used for bacterial detection and identification, e.g., Whipple’s disease.<sup>14</sup>

The sterility test media may be incapable of detecting a contaminated product. For example, in 2002 and 2003 there were three clusters of three outbreaks of clostridial disease caused by *Clostridium sordelli* in cows and sheep in Spain. Ironically, the outbreaks were linked to anti-clostridial vaccines, all produced by the same manufacturer, that were intrinsically contaminated with the same strain of *C. sordelli*.<sup>15</sup> The vaccine batches were released to the market using the harmonized sterility test. The majority of vials (93%) from the implicated batches contained low counts of *C. sordelli* when cultured on sulfite-polymyxin-sulfadiazine agar incubated under anaerobic conditions at 37° for up to 60 days. The fluid thioglycollate medium used in the sterility test failed to detect the clostridial contamination, presumably due to thioglycollate inhibition and the shorter incubation time.

### **Sample Quantity**

The minimum number of articles tested and quantity per container tested per media are defined in *Sterility Tests* <71>, *Table 2 and 3*. Whereas this sampling plan is suitable for manufactured pharmaceuticals, it is unsuitable for products generated by sterile compounding pharmacies, PET facilities, and cell therapy centers because of their small batch size, high cost, and therapeutic value to the individual patient. A further consideration is the sample size limitation of the advanced technology (see *Table 6*). Alternative sampling plans have been proposed, as discussed in *Sample Size Limitations* above.

### **Sample Preparation**

The complexity and number of steps in the sample preparation process add to the analyst's hands-on time, as well as the overall reduced recovery of the signal of viable microbial cells. Furthermore, to obtain a high throughput and short time to results, one needs an easy sample preparation. However, a complex sample preparation may be acceptable if the method provides improvements in time to results and LOD or has the potential to be automated. PET drugs and radiopharmaceuticals have added requirements associated with the safe handling of radioactive materials and the need for effective shielding to reduce radiation exposure to acceptable level.

### **Aseptic Test Material Handling: Open vs. Closed Systems**

Advanced technologies with closed systems will mitigate risk of microbial contamination with live organisms or their artifacts, such as adenosine triphosphate (ATP) or nucleic acid. With open systems, a decision may be made at the testing laboratory to conduct the testing in an isolator system, which adds to the expense and reduces testing throughout.

## Potential Trade-Off Between Conflicting User Requirements

There are obvious trade-offs between LOD, sample size, and time to results (see *Table 6*). Detecting a contaminated unit prior to administration is paramount in improving patient safety, therefore the proposed compendial rapid sterility tests must be risk-based with the stakeholder selecting the technology that best serves the interests of their patients and the beyond-use dating of their products. For example, patient safety may be served even if the LOD is 10–100 viable microbial cells, if the test can be completed the same day that a low-volume radiotracer is compounded.

## Experience with Bacterially Contaminated Platelet Concentrates

The collective experience with the administration of human platelet concentrates is revealing. This cellular component, which is obtained from whole blood collection or apheresis, is stored on rocking platforms at ambient temperature for up to 7 days prior to transfusion. These units have been reported to have bacterial contamination rates of 0.05%–0.2%. Based on the measurement of the contamination of transfused platelet concentration it was apparent the rates of septic reactions were about 50 times less and fatality rates were about 250 times lower (see *Table 5*). This supports the view that an infectious intravenous dose is not 1 cfu but the order of 10–100 CFU.<sup>10</sup>

**Table 5: Rates of Contamination, Septic Reactions, and Deaths with Administration of Platelet Concentrates**

Contamination Rate per Units Transfused	Rate of Septic Reactions per Unit Transfused	Fatality Rate per Units Transfused
0.05% (5000 contaminated units/million units transfused annually)	1%-1.3% of the contaminated units (10-13 septic reactions/million units)	15% - 20% of the septic reactions (2 deaths/million units)

From the FDA Draft Guidance for Industry: "Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion," March 2016

## Selection of Available Technologies with Potential for Use as a Rapid Sterility Test

The Expert Panel selected the following six analytical platforms, listed alphabetically, as candidates for compendial rapid sterility testing:

- Adenosine triphosphate bioluminescence
- Flow cytometry
- Isothermal microcalorimetry
- Nucleic acid amplification
- Respiration
- Solid phase cytometry

## Brief Descriptions of the Six Analytical Platforms

Each of these candidate advanced analytical platforms is briefly discussed below, and key references are provided. For an overview, the reader is referred to the 4-volume series of the *Encyclopedia of Rapid Microbiological Methods*, edited by Michael J. Miller, and a book dedicated to the topic, *Rapid Sterility Testing*, edited by Jeanne Moldenhauer.

### Adenosine Triphosphate Bioluminescence

This is a well-established technology that uses luminometers and reagents available from multiple instrument manufacturers. The energy from living cells is stored as ATP, which can be measured as light when exposed to luciferase from the American firefly. Each ATP molecule consumed by luciferase produces 1 photon of light. The result detected by a luminometer is typically expressed in relative light units (RLU) and is instrument-, reagent-, and organism-dependent. The ATP content of different microorganisms ranges from  $2\text{--}4 \times 10^{-18}$  mol/cfu for Gram-negative bacteria,  $5\text{--}8 \times 10^{-18}$  mol/cfu for Gram-positive bacteria, and  $300\text{--}800 \times 10^{-18}$  mol/cfu for fungi.<sup>16</sup> Given the high signal-to-noise ratio, the microbiologically relevant instrument detection limit is on the order of 5000 RLU, equivalent to  $10^3$  cfu.

This LOD will detect the presence of microorganisms at 3–4 log lower numbers within an aliquot of the media than that required for visual detection of growth in the media. For a sterility test, an enrichment culture, either in liquid media or on a membrane filter on solid media, could be used with an incubation time of 2–7 days.

### Flow Cytometry

Flow cytometry may be used to detect fluorescently labeled viable microbial cells after an enrichment culture step that takes 24–48 h.<sup>17</sup> A labeling reagent consisting of either a fluorogenic substrate or vital stain is used to differentiate viable cells from dead cells and cellular debris. Cell viability is indicated by the ability of the intact cell membrane to retain a fluorochrome generated by non-specific cellular esterase, or by labeling the cell with nucleic acid-specific vital stain. An argon laser illuminates each cell in the flow stream and the emitted light is detected by a dual photomultiplier array. The signal is digitized and interpreted by discrimination software. Instrumentation and reagents may be obtained from multiple vendors. The LOD for this technology may be, in the best case scenario, 10–100 viable microbial cells in the absence of a high-particulate background, so an enrichment/concentration step would be necessary unless a higher LOD than 1 cfu is accepted.

## Isothermal Microcalorimetry

Isothermal microcalorimeters monitor enthalpy changes in closed vials (systems) related to microbial metabolic activity and growth. With current instruments,  $10^4$  active microbial cells can release enough heat to be detected, although enrichment is needed for detection (2–7 days to result). The system has its origin in the cement and explosive industry. Within the past several years its use in biology started to receive more attention, and it is being applied in geology (e.g., soil testing), parasitology, optimization of fermenting processes, the food industry (e.g., monitoring of microbial growth in milk fermentation processes), clinical applications, and dentistry.<sup>18</sup> Recently, the application of isothermal microcalorimetry in pharmaceutical microbiology has also been evaluated.<sup>19</sup>

## Nucleic Acid Amplification

Real-time quantitative PCR has the potential to monitor the exponential phase of PCR through 36–48 cycles of amplification using universal primers to estimate the initial quantity of the target DNA, which is in turn proportional to the number of microbial cells in the test sample. Unlike DNA, cellular RNA has a rapid metabolic turnover and is a better indicator of viable microorganisms. For example, *E. coli* contains 2 molecules of DNA and 20,000 molecules of 16S rRNA/cell.<sup>20</sup> This process is achieved by the conversion of RNA into a complimentary copy of DNA by the enzyme reverse transcriptase and can be analyzed in real time in either a quantitative assay (enumeration test) or qualitative assay (sterility test). Alternatively, for DNA-based PCR, a sample pre-treatment with ethidium monoazide or propidium monoazide may allow for differentiation between live and dead microbial cells.<sup>21,22</sup>

Realistically, an LOD of 1 viable cell is probably an insurmountable challenge, especially for a test that relies on a DNA/RNA target and universal primers.

Generally, the LOD ranges from 10–1000 viable cells/mL of sample, and in some reported cases it ranges from 10–100 viable cells/mL. Recently it was shown that PCR may actually achieve detection of microorganisms with a limit of  $10^2$  -  $10^3$  cfu/mL in a sample containing a high concentration of up to  $10^6$  mammalian cells/mL without the need for pre-incubation in microbial growth media.<sup>23</sup>

Adding a growth-based enrichment step for at least 24–48 h and comparing the PCR results before and after enrichment may provide a practical solution for sterility testing. Alternatively, concentration methods could be applied to enrich the sample and reduce the sample volume. Instrumentation and reagents may be sourced from multiple vendors.

The higher LOD of 10–100 viable cells/mL does not mean that PCR methods are unsuitable for sterility testing. Jacobs, et al.<sup>10</sup> reported the relationship between the bacterial load and transfusion reactions with platelet concentrates. Based on the data reported they conclude that a threshold of 1000 cfu/mL would detect more than 95% of all cases of contamination and 90% of the reactions, whereas

a 100 cfu/mL threshold would detect all cases (100%). Data derived from transfusion medicine are particularly useful (see *Table 5*), and are used for patients undergoing bone marrow transplantation or receiving chemotherapy.

Use of non-growth based sterility tests such as PCR increases patient safety for the following reasons:

- With sterility testing that is close to real-time, the test is completed before the short-lived product is infused into a patient
- Culture-negative infectious agents are isolated
- The test is unaffected by antibiotics in the test sample
- The test is less sensitive to background noise resulting from animal cell lysis (e.g., particles, ATP), as compared to other technologies, because specific microbial genes are targeted

## Respiration

This broad category ranges from classical respirometers to gaseous headspace analyzers to automated blood culture systems. The use of automated blood culture systems has been successfully extended to sterility testing of cell therapy products. In 2004, the FDA approved a supplement to the biologics license held by Genzyme Biosurgery for Carticel, autologous cultured chondrocytes, to use the BacT/ALERT™ Microbial Detection System with a 7-day incubation as an alternative to the compendial sterility test for lot release.<sup>24</sup>

Other instruments are available to detect and enumerate respiring microorganisms. For example, tunable diode laser absorption spectroscopy (TDLAS) can measure O<sub>2</sub> depletion or CO<sub>2</sub> increase in closed units containing growing microorganisms in culture medium. The system was developed to monitor gas headspace composition in closed units and also could be used for automatic media fill inspection.<sup>19,25</sup> TDLAS has gaseous calibration standards, and minor adaptations are needed if the system is to be used for sterility testing (e.g., calibrating for higher-volume containers).

Note that all the systems of the respiration platform require microbial growth and metabolic activity for detection, i.e., the usual time to result of 2–7 days is required. However, the results can be progressively monitored to detect a sterility test failure earlier in the incubation period, which is a huge advantage with short-life products.

## Solid-Phase Cytometry

Several instrument manufacturers market systems based on solid-phase cytometry. For instance, the ScanRDI® microbial analysis system has the most market experience and combines fluorescent labeling and solid-phase laser scanning cytometry to rapidly enumerate viable microorganisms in filterable liquids.<sup>26</sup> Cells are collected by filtration on 0.45-µm polyester membranes and treated

with background and viability stains. The filters are scanned in a cytometer by a high-speed, 488-nm argon laser. Fluorescence is detected by multiple photomultiplier tubes and processed to differentiate between labeled microorganisms and background noise. The scan is displayed as map that identifies the positions of the fluorescent events, which are verified using an epifluorescence microscope with an automated motorized stage to locate the individual events. The system is claimed to identify individual viable microorganisms in 2–3 h.

In *Table 6*, the critical operating parameters of representative candidate modern microbiological methods are provided for informational purposes. These values are estimated, and may be optimistic in some cases. The list is not all-inclusive and does not constitute an endorsement of any single technology.

**Table 6: Operational Parameters of Candidate Technologies**

Representative Detection System	Technology	Limit of Detection (cfu/mL)	Time to Result	Sample Size (mL)
Gram stain	Classical	10 <sup>4</sup> - 10 <sup>5</sup>	30 min	0.1
BacT/ALERT System	Respiration	1-10	Overnight - 7 days	5-10
ScanRDI System	Solid-phase cytometry	1-10	2-3 h	1-500
Milliflex Rapid System	ATP bioluminescence	1-10	5-7 days	1-500
FACS analysis	Flow cytometry	10-100	6-8 h (pre-enrichment)	0.1-2
Roche LightCycler	Nucleic acid amplification	1-100	2-4 h	0.2-2
TAM V	Isothermal microclorimetry	1-10	2-7 days	1

### Representative Instrumentation Manufacturers of the Candidate Technologies

One requirement for an analytical platform to be considered as a compendial sterility test is that it is nonproprietary and there are multiple vendors for the technology and associated reagents. Although it is not all-inclusive, *Table 7* provides more details of the justification based on this requirement.

**Table 7: Commercially Available Instrumentation Showing Multiple Vendors**

Advanced Technology	Instrument Name	Vendor
ATP bioluminescence	<p>Biotrace 2000</p> <p>Pallcheck Rapid System</p> <p>Milliflex Rapid System</p> <p>Celsis RapiScan</p> <p>BioMAYTECTOR</p>	<p>Biotrace International, Brigend, UK</p> <p>Pall Corp., Port Washington, NY</p> <p>Millipore Corp., Bedford, MA</p> <p>Charles River Laboratories, Inc., Wilmington, MA</p> <p>Hitachi Plant Technologies, Tokyo, Japan</p>
Flow cytometry	<p>Bact-Flow</p> <p>FACSMicroCount</p>	<p>bioMerieux, Hazelwood, MO</p> <p>Becton, Dickerson &amp; Co., Sparks, DE</p>
Isothermal microcalorimetry	<p>TAM III Calorimeter</p> <p>Biocal 2000 Isothermal Calorimeter</p> <p>48-challen isothermal microcalorimeter</p>	<p>TA Instruments, Wilmington, DE</p> <p>Calimetrix, Arlington, MA</p> <p>SymCell Sverige, Kista, Sweden</p>
Nucleic acid amplification	<p>Multiple thermocyclers and amplicor analyzers</p>	<p>Roche Applied Science, Indianapolis, IN</p> <p>Applied Biosystems, Foster City, CA</p> <p>Cepheid, Sunnyvale, CA</p>
Respiration	<p>Promex Microrespirator 4200</p> <p>BACTEC System</p> <p>BioLumix</p> <p>BacT/ALERT 3D Dual-T System</p> <p>eBDS Pall System</p> <p>TDLS</p>	<p>PromChem Ltd., Edenbridge, UK</p> <p>BD Diagnostics, Sparks, DE</p> <p>BioLumix, Ann Arbor, MI</p> <p>bioMerieux, Hazelwood, MO</p> <p>Pall Corp., Port Washington, NY</p> <p>Lighthouse Instruments, Charlottesville, VA</p>
Solid phase cytometry	<p>ScanRDI® System</p> <p>BioSafe PTS</p> <p>MuScan System</p>	<p>bioMerieux, Hazelwood, MO</p> <p>Charles River Laboratories, Inc., Wilmington, MA</p> <p>Innosieve Diagnostics, Wageningen, The Netherlands</p>

The path forward for the adoption of these analytical platforms as compendial tests for short-lived products includes 1) writing an informational general chapter on risk-based sterility testing, 2) collaborative development of generic rapid sterility tests and validation of the selected test methods, and 3) writing and publishing them as official USP tests.

## References

1. United States Pharmacopeial Convention (2017). <71> sterility tests. In *United States Pharmacopeia and National Formulary* (USP 40th ed. & NF 35th ed.). Rockville, MD: United States Pharmacopeial Convention, Inc.
2. Cundell, A. M. (2002). Review of the media selection and incubation conditions for the compendial sterility and microbial limit tests. *Pharmacopeial Forum*, 28(6), 2034–2041.
3. Cundell, A. M. (2011). The history of the development, applications, and limitations of the USP sterility test. *Rapid Sterility Tests*, 7, 127-170.
4. Sutton, S. (2011). Sterility tests. *Rapid Sterility Tests*, 7, 7-28.
5. Van Doorne, H., Van Kampen B. J., Van der Lee, R. W., Rummenie, L., Van der Veen, A. J., & De Vries, W. J. (1998). Industrial manufacture of parenteral products in The Netherlands: A survey of eight years of media fills and sterility testing. *PDA Journal of Pharmaceutical Science & Technology*, 52(2), 159-164.
6. Bathgate, H., Lazzari, D., Cameron, H., & McKay, D. (1993). The incubation period in sterility testing. *PDA Journal of Pharmaceutical Science & Technology*, 47(5), 254–257.
7. The Pew Charitable Trusts. (2015). *U.S. illnesses and deaths associated with compounded medications or repackaged medications*. Retrieved from <http://www.pewtrusts.org/en/research-and-analysis/data-visualizations/2014/us-illnesses-and-deaths-associated-with-compounded-medications>
8. Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004). Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. *Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America*, 39(3), 309–317.
9. Leggett, H. C., Cornwallis, C. K., & West, S. A. (2012). Mechanisms of pathogenesis, infective dose and virulence in human parasites. *PLOS Pathogens*, 8(2). <https://dx.doi.org/10.1371%2Fjournal.ppat.1002512>
10. Jacob, M. R., Good, C. E., Lazarus, H. M., & Yomtovian, R. A. (2008). Relationship between bacterial load, species virulence, and transfusion reaction with transfusion of bacterially contaminated platelets. *Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America*, 46, 1214–1220.
11. Hong, H., Xiao, W., Lazarus, H. M., Good, C. E., Maitta, R. W., & Jacobs, M. R. (2016). Detection of septic transfusion reactions to platelet transfusions by active and passive surveillance. *Blood*, 127(4), 496–502.
12. Benjamin, R. J. (2016). Transfusion-related sepsis: A silent epidemic. *Blood*, 127(4), 380–381.
13. Tokuno, O., Hayakawa, A., Yanai, T., Mori, T., Ohnuma, K., Tani, A., Minami, H., & Sugimoto, T. (2015). Sterility testing of stem cell products by broad-range bacterial 16S ribosomal DNA polymerase chain reaction. *Laboratory Medicine*, 46(1), 8-41.
14. Versalovic, J., Carroll, K. C., Funke, G., Jorgensen, J. H., Landry, M. L., & Warnock, D. W. (Eds.). (2011). *Manual of Clinical Microbiology, 10th Edition* (1035-1039). Washington, D.C.: ASM Press.
15. Téllez, S., Casimiro, R., Vela, A. I., Fernández-Garayzabal, J. F., Ezquerro, R., Latre, M. V., Briones, V., Goyache, J., Bullido, R., Arboix, M., & Domínguez, L. (2006). Unexpected inefficiency of the European Pharmacopoeia sterility test for detecting contamination in clostridial vaccines. *Vaccine*, 24(10), 1710–1715.
16. La Duc, M. T., Dekas, A., Osman, S., Moissl, C., Newcombe, D., & Venkateswaran, K. (2007) Isolation and characterization of bacteria capable of tolerating the extreme conditions of clean room environments. *Applied and Environmental Microbiology*, 73(8), 2600-2611.
17. Baumstummeler, A., Chollet, R., Meder, H., Rofel, C., Venchiarutti, A., & Ribault, S. (2010). Detection of microbial contamination in mammalian cell cultures using a new fluorescence-based staining method. *Letters in Applied Microbiology*, 51(6), 671–677.

18. Braissant, O., Bonkat, G., Wirz, D., & Bachmann, A. (2013). Microbial growth and isothermal microcalorimetry: Growth models and their application to microcalorimetric data. *Thermochimica Acta*, *555*, 64– 71.
19. Brueckner, D., Roesti, D., Zuber, U. G., Schmidt, R., Kraehenbuehl, S., Bonkat, G., & Braissant, O. (2016). Comparison of tunable diode laser absorption spectroscopy and isothermal microcalorimetry for non-invasive detection of microbial growth in media fills. *Scientific Reports*, *6*. doi: 10.1038/srep27894
20. Tumbler, K., & Milo, R. (1990). Overall macromolecular composition of *E. coli*. In Neidhardt, F. C., Ingraham, J. L., & Schaechter, M. *Physiology of the bacterial cell: A molecular approach*. Coventry, UK: Elsevier Inc.
21. Patel, P., Garson, J. A., Tettmar, K.I., Ancliff, S., McDonald, C., Pitt, T., Coelho, J., & Tedder, R.S. (2012). Development of an ethidium monoazide-enhanced internally controlled universal 16S rDNA real-time polymerase chain reaction assay for detection of bacterial contamination in platelet concentrates. *Transfusion*, *52*(7), 1423–1432.
22. Nocker, A., Cheung, C. Y., & Camper, A.K. (2006). Comparison of propidium monoazide with ethidium monoazide for differentiation of live vs. dead bacteria by selective removal of DNA from dead cells. *Journal of Microbiological Methods*, *67*(2), 310–320.
23. Kleinschmidt, K., Wilkens, E., Glaeser, S. P., Kaempfer, P., Staerk, A., & Roesti, D. (2016). Development of a qualitative real-time PCR for microbiological quality control testing in mammalian cell culture production. *Journal of Applied Microbiology*, *122*, 997-1008.
24. Kielpinski, G., Prinzi, S., Duguid, J., & du Moulin, G. (2005). Roadmap to approval: Use of an automated sterility test method as a lot release test for Carticel, autologous cultured chondrocytes. *Cytotherapy*. *7*(6), 531-541.
25. Duncan, D., Cundell, T., Levac, L., Veale, J., Kuiper, S., & Rao, R. (2016). The Application of Noninvasive Headspace Analysis to Media Fill Inspection. *PDA Journal of Pharmaceutical Science & Technology*, *70*(3), 230–247.
26. Smith, R., Von Tress, M., Tubb, C., & Vanhaecke, E. (2010). Evaluation of the ScanRDI as a rapid alternative to the pharmacopoeial sterility test method: Comparison of limits of detection. *PDA Journal of Pharmaceutical Science and Technology*, *64*(4), 356-363.

<sup>a</sup> USP Modern Microbiological Methods Expert Panel Members (Listed alphabetically with affiliation): Thierry Bonnevey, Sanofi Pasteur; Randolph Breton, Infuserve; Claudio Denoya, Particle Measuring Systems Technology; Anthony M. Cundell, USP Microbiology Expert Committee (Co-chair); John Duguid, Vericel; Matthew Jenkins, UVA Medical Center; Felix Montero Julian, bioMerieux; James Kenney, FDA/CBER; Amy McDaniel, Pfizer; Michael Miller, Microbiology Consultants, LLC; Gary du Moulin, Massachusetts College of Pharmacy and Health Sciences; David Newton, USP Compounding Expert Committee; David Hussong, Chair, USP Microbiology Expert Committee; Kuldip Patel, Duke University Hospital; Steven Richter, Microtest Laboratories; David Roesti, USP Microbiology Expert Committee; Edward Tidswell, USP Microbiology Expert Committee (Co-chair); Yongqiang Zhang, BD; Steven Zigler, USP Chemical Medicines Expert Committee.

<sup>b</sup> Disclaimer: The views presented in this article do not necessarily reflect those of the organizations for which the authors work. No official support or endorsement by these organizations is intended or should be inferred.

<sup>c</sup> Disclaimer: Certain commercial equipment, instruments, vendors, or materials are identified in this Stimuli article for informational purposes. Such identification does not imply approval, endorsement, or certification by USP of a particular brand or product, nor does it imply that the equipment, instrument, vendor, or material is necessarily the best available for the purpose or that any other brand or product was judged to be unsatisfactory or inadequate. All product names, logos, and brands are property of their respective owners

<sup>d</sup> The conflicts of interest of the named authors of this article are as follows: Yongqiang Zhang is employed by BD Biosciences; Felix Montero Julian is employed by bioMerieux; Anthony M. Cundell and Michael J. Miller consult with some of the technology vendors indicated in this article

<sup>e</sup> Correspondence should be addressed to: Radhakrishna S.Tirumalai, Ph.D., Principal Scientific Liaison-General Chapters, US Pharmacopoeial Convention, 12601 Twinbrook Parkway, Rockville, MD 20852-1790; tel 301-816-8339; e-mail: rst@usp.org.



**Eagle Analytical Services, Inc.**

9940 W. Sam Houston Parkway S., Suite 310, Houston, TX 77099  
832.295.1276 | [www.eagleanalytical.com](http://www.eagleanalytical.com)